AstraZeneca Plc reported better-than-expected profit and sales in the fourth quarter and forecast further gains as the UK drugmaker’s blockbuster cancer drugs offset weakened China sales.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback